In a welcome move, Smith & Nephew ADR saw its Relative Strength Rating rise from 64 to 71 on Thursday.
When To Sell Stocks To Lock In Profits And Minimize Losses
This exclusive rating from Investor's Business Daily identifies share price performance with a 1 (worst) to 99 (best) score. The score shows how a stock's price behavior over the last 52 weeks holds up against all the other stocks in our database.
Over 100 years of market history reveals that the stocks that go on to make the biggest gains often have an RS Rating of over 80 in the early stages of their moves. See if Smith & Nephew ADR can continue to rebound and hit that benchmark.
Smith & Nephew ADR is trying to complete a consolidation with a 31.72 buy point. See if it can break out in volume at least 40% higher than normal.
The company showed -2% EPS growth in its most recent report. Sales gains came in at 6%.
Smith & Nephew ADR holds the No. 23 rank among its peers in the Medical-Products industry group. TransMedics Group, Insulet and LifeMD are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Which Stocks Are Showing Improved Price Performance?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
